Takeda Pharmaceuticals Australia Launches Reflect Reconciliation Action Plan (RAP)

May 8, 2025

Takeda’s RAP outlines its strategy to build meaningful relationships, deepen cultural understanding, and create new opportunities for First Nations Peoples through a structured framework grounded in three core pillars: Relationships, Respect, and Opportunities. This initiative underscores Takeda’s dedication to reconciliation and a more inclusive, equitable society.

Reflecting on the significance of the initiative, RAP Co-Chairs Simone Smith and Colleen McArthur said, “Our RAP represents Takeda’s commitment to continuous learning through experience, connection, and listening with open hearts and minds. At the heart of this journey is the fostering of relationships and trust between our employees and Aboriginal and Torres Strait Islander Peoples."

As part of the RAP’s launch, Takeda unveiled a special artwork titled Brighter Futures, created by renowned Aboriginal artist Susan Duliny Reys. The artwork symbolises the connection between nature, health, and Takeda’s vision for reconciliation. Central elements such as the Wattle tree, important to Aboriginal cultures both spiritually and medicinally, and Takeda’s Cherry Blossom tree, representing the company’s heritage and sustained future, reflect harmony between First Nations Peoples and Takeda’s identity.

Dave Pearce, General Manager of Takeda Oceania, remarked, “With a heritage spanning over 240 years, Takeda is committed not only to delivering innovative medicines but also to fostering reconciliation within Australia. It is the shared responsibility of every individual and organisation to work collaboratively to improve health outcomes for all Australians, including Aboriginal and Torres Strait Islander Peoples.”

Healthcare is a key area where reconciliation and equity align closely. By embedding cultural awareness into healthcare practices, Takeda aims to address gaps in healthcare access and equity. Through initiatives outlined in the RAP, the company seeks to improve service delivery and health outcomes while contributing to reconciliation efforts in its industry.

Takeda is honoured to have its Reflect RAP endorsed by Reconciliation Australia and looks forward to taking steps that contribute to meaningful reconciliation while improving health equity for Aboriginal and Torres Strait Islander Peoples and fostering stronger relationships across its operations.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Media Contacts:

Takeda Oceania Communications

[email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Takeda Pharmaceuticals Australia is proud to announce the launch of its second Reflect Reconciliation Action Plan (RAP), marking a significant step in the company’s commitment to fostering meaningful relationships, respect, and trust with Aboriginal and Torres Strait Islander Peoples. Takeda’s RAP outlines its strategy to build meaningful relationships, deepen cultural understanding, and create new opportunities for First Nations Peoples through a structured framework grounded in three core pillars: Relationships, Respect, and Opportunities. This initiative underscores Takeda’s dedication to reconciliation and a more inclusive, equitable society. Reflecting on the significance of the initiative, RAP Co-Chairs Simone Smith and Colleen McArthur said, “Our RAP represents Takeda’s commitment to continuous learning through experience, connection, and listening with open hearts and minds. At the heart of this journey is the fostering of relationships and trust between our employees and Aboriginal and Torres Strait Islander Peoples." As part of the RAP’s launch, Takeda unveiled a special artwork titled Brighter Futures, created by renowned Aboriginal artist Susan Duliny Reys. The artwork symbolises the connection between nature, health, and Takeda’s vision for reconciliation. Central elements such as the Wattle tree, important to Aboriginal cultures both spiritually and medicinally, and Takeda’s Cherry Blossom tree, representing the company’s heritage and sustained future, reflect harmony between First Nations Peoples and Takeda’s identity. Dave Pearce, General Manager of Takeda Oceania, remarked, “With a heritage spanning over 240 years, Takeda is committed not only to delivering innovative medicines but also to fostering reconciliation within Australia. It is the shared responsibility of every individual and organisation to work collaboratively to improve health outcomes for all Australians, including Aboriginal and Torres Strait Islander Peoples.” Healthcare is a key area where reconciliation and equity align closely. By embedding cultural awareness into healthcare practices, Takeda aims to address gaps in healthcare access and equity. Through initiatives outlined in the RAP, the company seeks to improve service delivery and health outcomes while contributing to reconciliation efforts in its industry. Takeda is honoured to have its Reflect RAP endorsed by Reconciliation Australia and looks forward to taking steps that contribute to meaningful reconciliation while improving health equity for Aboriginal and Torres Strait Islander Peoples and fostering stronger relationships across its operations. ## About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](https://www.takeda.com/). ### Media Contacts: Takeda Oceania Communications [[email protected]](mailto:[email protected]) ## Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.